Frangou et al (Reference Frangou, Lewis and McCrone2006) reported ethyleicosapentaenoic acid (ethyl-EPA) to be effective in the treatment of bipolar depression. However, no mention is made of the dietary intake of ethyl-EPA among the randomised groups. Ethyl-EPA is a naturally occurring substance and hence a potential confounding variable. The statistically significant improvements in the ethyl-EPA group(s) compared with placebo in terms of decreases in scores on the Hamilton Rating Scale for Depression and the Clinical Global Impression Scale could simply have been a result of differences in dietary ethyl-EPA intake. Such a difference is likely to have involved increased intake in the ethyl-EPA group(s), but decreased intake in these groups could have lessened any potential improvements. Further studies of omega-3 fatty acids must control for the potential confounding independent variable of dietary intake.
Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Safa, Mitra
Fallah Tafti, Saeed
Ghassem Boroujerdi, Fatemeh
and
Talischi, Firouzeh
2013.
Clinical trial in the treatment of 80 Iranian patients with major depression disorder by the combination of omega 3 fatty acid and a selective serotonin reuptake inhibitor.
Therapeutic Advances in Psychopharmacology,
Vol. 3,
Issue. 4,
p.
186.
eLetters
No eLetters have been published for this article.